Advances and challenges in drug design of PPARδ ligands (2018)
Source: Current Drug Targets. Unidades: ICB, FCF, EACH
Subjects: DIABETES MELLITUS NÃO INSULINO-DEPENDENTE, SÍNDROME X METABÓLICA, ÁCIDOS GRAXOS, DOENÇAS METABÓLICAS, PARASITOLOGIA
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
MALTAROLLO, Vinícius Gonçalves et al. Advances and challenges in drug design of PPARδ ligands. Current Drug Targets, v. 19, n. 2, p. 144-154, 2018Tradução . . Disponível em: https://doi.org/10.2174/1389450118666170414113159. Acesso em: 04 set. 2024.APA
Maltarollo, V. G., Kronenberger, T., Windshuegel, B., Wrenger, C., Trossini, G. H. G., & Honório, K. M. (2018). Advances and challenges in drug design of PPARδ ligands. Current Drug Targets, 19( 2), 144-154. doi:10.2174/1389450118666170414113159NLM
Maltarollo VG, Kronenberger T, Windshuegel B, Wrenger C, Trossini GHG, Honório KM. Advances and challenges in drug design of PPARδ ligands [Internet]. Current Drug Targets. 2018 ; 19( 2): 144-154.[citado 2024 set. 04 ] Available from: https://doi.org/10.2174/1389450118666170414113159Vancouver
Maltarollo VG, Kronenberger T, Windshuegel B, Wrenger C, Trossini GHG, Honório KM. Advances and challenges in drug design of PPARδ ligands [Internet]. Current Drug Targets. 2018 ; 19( 2): 144-154.[citado 2024 set. 04 ] Available from: https://doi.org/10.2174/1389450118666170414113159